Showing results (1-10 of 404) with videos related to
Sort By:
Pageof 41
Medical Oncology (Northwood, London, England)|March 15, 2011
Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the betterFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|July 31, 2012
Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regressionFausto Petrelli, Sandro BarniRadiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 18, 2011
Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trialsFausto Petrelli, Sandro BarniBreast Cancer Research and Treatment|November 2, 2013
Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancerFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|March 3, 2010
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debateFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|July 2, 2013
Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trialsFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|November 26, 2013
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trialsFausto Petrelli, Sandro BarniTranslational Lung Cancer Research|March 26, 2015
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trialsFausto Petrelli, Sandro BarniHead & Neck|September 29, 2011
Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysisFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|December 17, 2010
Bevacizumab in advanced breast cancer: an opportunity as second-line therapy?Fausto Petrelli, Sandro BarniPageof 41